Insulin lispro biosimilar (Geropharm)

赖脯胰岛素生物类似药 (Geropharm)

Report date: 2024/04/18 20:00:32

Base Information

Drug NameInsulin lispro biosimilar (Geropharm)

Drug Alias NameInsulin Lispro Mix 25赖脯胰岛素生物仿制药 (Geropharm)Insulin lispro biphasic biosimilar - Geropharm

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar

Mechanisms of ActionInsulin receptor agonists

TargetsInsulin receptor

Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGeropharm

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesGeropharm

Active IndicationsN/A

Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus

ATC CodeA10AB04A10AC04A10AD04